Clinical Trial Supply And Logistics Market (By Service: Logistics & Distribution, Storage & Retention, Packaging, Labeling, and Blinding, Manufacturing, Comparator Sourcing, Other Services (Solutions, Ancillary Supply); By Phase: Phase I, Phase II, Phase III, Phase IV; By End-user: Pharmaceuticals, Biologicals, Medical Device; By Therapeutic Area: Oncology, Cardiovascular Diseases, Respiratory Diseases, CNS and Mental Disorders, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and End-user Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Clinical Trial Supply And Logistics Market, By Service

7.1.  Clinical Trial Supply And Logistics Market, by Service, 2021-2030

7.1.1.    Logistics & Distribution

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Storage & Retention

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Packaging, Labeling, and Blinding

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Manufacturing

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Comparator Sourcing

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    Other Services (Solutions, Ancillary Supply)

7.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Clinical Trial Supply And Logistics Market, By Phase

8.1.  Clinical Trial Supply And Logistics Market, by Phase, 2021-2030

8.1.1.    Phase I

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase II

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase III

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase IV

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Clinical Trial Supply And Logistics Market, By End-user

9.1.  Clinical Trial Supply And Logistics Market, by End-user, 2021-2030

9.1.1.    Pharmaceuticals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Biologicals

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Medical Device

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Clinical Trial Supply And Logistics Market, By Therapeutic Area

10.1.        Clinical Trial Supply And Logistics Market, by Therapeutic Area, 2021-2030

10.1.1.  Oncology

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Cardiovascular Diseases

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Respiratory Diseases

10.1.3.1.      Market Revenue and Forecast (2017-2030)

10.1.4.  CNS and Mental Disorders

10.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Clinical Trial Supply And Logistics Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Service (2017-2030)

11.1.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.1.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.1.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Service (2017-2030)

11.2.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.2.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.2.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Service (2017-2030)

11.3.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.3.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.3.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Service (2017-2030)

11.4.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.4.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.4.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Service (2017-2030)

11.5.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.5.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.5.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

Chapter 12.  Company Profiles

12.1.              Piramal Pharma Solutions

12.1.1.  Company Overview

12.1.2.  Service Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              UDG Healthcare

12.2.1.  Company Overview

12.2.2.  Service Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              DHL

12.3.1.  Company Overview

12.3.2.  Service Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              FedEx

12.4.1.  Company Overview

12.4.2.  Service Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Movianto

12.5.1.  Company Overview

12.5.2.  Service Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Packaging Coordinators Inc.

12.6.1.  Company Overview

12.6.2.  Service Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Thermo Fisher Scientific (Patheon)

12.7.1.  Company Overview

12.7.2.  Service Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Catalent, Inc.

12.8.1.  Company Overview

12.8.2.  Service Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Parexel

12.9.1.  Company Overview

12.9.2.  Service Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Almac Group

12.10.1.               Company Overview

12.10.2.               Service Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms